Vyome Announces Executive Management Appointment

Vyome Therapeutics announced the appointment of Craig Tooman as the Chief Operating Officer (COO) and Chief Financial Officer (CFO). Tooman brings more than 25 years of operating, financial, and M&A experience in the biotechnology and pharmaceutical industries.

"It is with great pleasure and excitement that we welcome Craig to the Vyome team," said Venkat Nelabhotla, President and Chief Executive Officer of Vyome Therapeutics. "Craig is a seasoned industry executive with many years of experience as a biopharma CFO, during which he created and built companies and led the raise of over $5.5 billion in capital. This wealth of experience building life sciences companies and leading successful financing initiatives, including IPOs and mergers and acquisitions, will prove to be invaluable as Vyome continues to advance its pipeline."

"Vyome’s locally-acting, next generation drug candidates represent an exciting and promising new approach to treating inflammation-driven diseases of unmet need. I’m thrilled to have the opportunity to work alongside the exceptional leadership team at Vyome, as well as help shape the company’s strategy as it continues improving current standards of care for inflammatory diseases and VB-1953 advances in the clinic," Craig Tooman, Chief Operating Officer and Chief Financial Officer of Vyome Therapeutics, said.

Prior to his position at Vyome, Tooman served as Chief Executive Officer of Aratana Therapeutics, a pet therapeutics company which merged with Elanco Animal Health in July, 2019. He also spent six years as the Chief Financial Officer and treasurer of Aratana. Aratana achieved an award-winning IPO in 2013. Previous to Aratana, Tooman served as founder and Chief Executive Officer of Avanzar Medical, an oncology company formed in conjunction with his role as the Entrepreneur in Residence (EIR) of Texas’ $2 billion CPRIT program. Prior to his time at Avanzar, Tooman served as Chief Financial Officer at Ikaria Inc. and Enzon Pharmaceuticals. Tooman has held a number of strategic roles within additional biopharma companies vital to the execution of major strategic and financial transactions including the combined acquisitions of over $1.4 billion by companies such as Sigma Tau and Genzyme (ILEX Oncology). He also played key roles in the successful evolution of Pharmacia and its predecessor companies including Upjohn. In addition to his roles as a corporate executive, Tooman has served as principal of Stockbourne since 2011, where he provides strategic business and financial advisory services for companies evaluating fund raising opportunities, product acquisition rights and strategic partnering ideas. Tooman has served on several company boards, including Insite Vision, Xanodyne Pharmaceuticals, and Aratana Therapeutics, and currently serves on the Board of CureVac. Tooman holds an MBA in finance from the University of Chicago and a B.A. in economics from Kalamazoo College.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.